|
gptkbp:instanceOf
|
gptkb:biotechnology
contract research organization
|
|
gptkbp:acquiredBy
|
gptkb:AppTec_Laboratory_Services
|
|
gptkbp:country
|
gptkb:China
|
|
gptkbp:foundedBy
|
gptkb:Ge_Li
|
|
gptkbp:foundedYear
|
2000
|
|
gptkbp:headquartersLocation
|
gptkb:Shanghai
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
WuXi PharmaTech
|
|
gptkbp:industry
|
gptkb:biotechnology
pharmaceuticals
|
|
gptkbp:keyPerson
|
gptkb:Ge_Li
gptkb:Zhaohui_Zhang
gptkb:Edward_Hu
|
|
gptkbp:listedOn
|
NYSE (delisted in 2015)
|
|
gptkbp:notableClient
|
global pharmaceutical companies
|
|
gptkbp:numberOfEmployees
|
over 30,000
|
|
gptkbp:parentCompany
|
gptkb:WuXi_AppTec
|
|
gptkbp:providesService
|
clinical research
drug discovery
laboratory services
manufacturing services
|
|
gptkbp:revenue
|
over $3 billion (2022)
|
|
gptkbp:servesArea
|
worldwide
|
|
gptkbp:stockExchange
|
gptkb:Hong_Kong_Stock_Exchange
|
|
gptkbp:stockSymbol
|
gptkb:2269.HK
|
|
gptkbp:subsidiary
|
gptkb:WuXi_Biologics
gptkb:WuXi_NextCODE
|
|
gptkbp:website
|
https://www.wuxiapptec.com/
|
|
gptkbp:bfsParent
|
gptkb:Zhangjiang
|
|
gptkbp:bfsLayer
|
6
|